List of Tables
Table 1: List of secondary sources
Table 2: List of Abbreviation
Table 3: Types of ADRs
Table 4: Adverse Drug Events (ADEs) in hospitals
Table 5: Pharmacovigilance outsourcing services insights
Table 6: List of regulations, by country
Table 7: Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 8: Case management costing by year
Table 9: Price by case processing volume
Table 10: Subscription services for medical manuscript writing
Table 11: Total literature searches (2013-2022)
Table 12: Instances of failed phase I clinical trials for COVID-19 vaccine
Table 13: Recruiting phase II clinical trials for oncology
Table 14: Outsourcing trend observed in pharmaceutical companies
Table 15: Recent Market Events
Table 16: List of Major Deals & Acquisitions
Table 17: North America pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 18: North America pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 19: North America pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 20: North America pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 21: North America pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 22: North America pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 23: U.S. pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 24: U.S. pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 25: U.S. pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 26: U.S. pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 27: U.S. pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 28: U.S. pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 29: Canada pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 30: Canada pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 31: Canada pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 32: Canada pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 33: Canada pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 34: Canada pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 35: Europe pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 36: Europe pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 37: Europe pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 38: Europe pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 39: Europe pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 40: Europe pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 41: UK pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 42: UK pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 43: UK pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 44: UK pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 45: UK pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 46: UK pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 47: Germany pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 48: Germany pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 49: Germany pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 50: Germany pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 51: Germany pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 52: Germany pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 53: France pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 54: France pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 55: France pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 56: France pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 57: France pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 58: France pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 59: Italy pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 60: Italy pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 61: Italy pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 62: Italy pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 63: Italy pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 64: Italy pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 65: Spain pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 66: Spain pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 67: Spain pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 68: Spain pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 69: Spain pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 70: Spain pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 71: Russia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 72: Russia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 73: Russia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 74: Russia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 75: Russia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 76: Russia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 77: Denmark pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 78: Denmark pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 79: Denmark pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 80: Denmark pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 81: Denmark pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 82: Denmark pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 83: Norway pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 84: Norway pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 85: Norway pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 86: Norway pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 87: Norway pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 88: Norway pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 89: Sweden pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 90: Sweden pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 91: Sweden pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 92: Sweden pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 93: Sweden pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 94: Sweden pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 95: Asia Pacific pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 96: Asia Pacific pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 97: Asia Pacific pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 98: Asia Pacific pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 99: Asia Pacific pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 100: Asia Pacific pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 101: Japan pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 102: Japan pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 103: Japan pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 104: Japan pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 105: Japan pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 106: Japan pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 107: China pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 108: China pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 109: China pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 110: China pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 111: China pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 112: China pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 113: India pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 114: India pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 115: India pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 116: India pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 117: India pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 118: India pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 119: Australia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 120: Australia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 121: Australia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 122: Australia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 123: Australia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 124: Australia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 125: Thailand pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 126: Thailand pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 127: Thailand pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 128: Thailand pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 129: Thailand pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 130: Thailand pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 131: South Korea pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 132: South Korea pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 133: South Korea pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 134: South Korea pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 135: South Korea pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 136: South Korea pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 137: Latin America pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 138: Latin America pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 139: Latin America pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 140: Latin America pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 141: Latin America pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 142: Latin America pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 143: Brazil pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 144: Brazil pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 145: Brazil pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 146: Brazil pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 147: Brazil pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 148: Brazil pharmacovigilance market, by end use, 2017- 2030 (USD Million
Table 149: Mexico pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 150: Mexico pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 151: Mexico pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 152: Mexico pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 153: Mexico pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 154: Mexico pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 155: Argentina pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 156: Argentina pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 157: Argentina pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 158: Argentina pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 159: Argentina pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 160: Argentina pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 161: MEA pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 162: MEA pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 163: MEA pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 164: MEA pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 165: MEA pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 166: MEA pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 167: South Africa pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 168: South Africa pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 169: South Africa pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 170: South Africa pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 171: South Africa pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 172: South Africa pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 173: Saudi Arabia pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 174: Saudi Arabia pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 175: Saudi Arabia pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 176: Saudi Arabia pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 177: Saudi Arabia pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 178: Saudi Arabia pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 179: UAE pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 180: UAE pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 181: UAE pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 182: UAE pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 183: UAE pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 184: UAE pharmacovigilance market, by end use, 2018-2030 (USD Million)
Table 185: Kuwait pharmacovigilance market, by service provider, 2018-2030 (USD Million)
Table 186: Kuwait pharmacovigilance market, by product life cycle, 2018-2030 (USD Million)
Table 187: Kuwait pharmacovigilance market, by type, 2018-2030 (USD Million)
Table 188: Kuwait pharmacovigilance market, by therapeutic area, 2018-2030 (USD Million)
Table 189: Kuwait pharmacovigilance market, by process flow, 2018-2030 (USD Million)
Table 190: Kuwait pharmacovigilance market, by end use, 2018-2030 (USD Million)
List of Figures
Fig. 1: Pharmacovigilance market segmentation
Fig. 2: Market research process
Fig. 3: Data triangulation techniques
Fig. 4: Primary research pattern
Fig. 5: Primary interviews in North America
Fig. 6: Primary interviews in Europe
Fig. 7: Primary interviews in APAC
Fig. 8: Primary interviews in Latin America
Fig. 9: Primary interviews in MEA
Fig. 10: Market research approaches
Fig. 11: Value-chain-based sizing & forecasting
Fig. 12: QFD modeling for market share assessment
Fig. 13: Market formulation & validation
Fig. 14: Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Fig. 15: Market Snapshot
Fig. 16: Segment Snapshot (Product Life Cycle & Service Provider)
Fig. 17: Segment Snapshot (Type & Therapeutic Area)
Fig. 18: Segment Snapshot (Process Flow & End Use))
Fig. 19: Competitive Landscape Snapshot
Fig. 20: Penetration & growth prospect mapping
Fig. 21: Pharmacovigilance market dynamics
Fig. 22: Porter’s five force model
Fig. 23: Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 24: Pharmacovigilance & Patient Safety Services - Product Life Cycle
Fig. 25: PV department
Fig. 26: PV organization structure
Fig. 27: Estimated budget allocation of drug safety activities at global and country-level
Fig. 28: Comparison between estimated global and country-level drug safety budget allocation
Fig. 29: Average % of drug safety budget contributed by function at a global level
Fig. 30: Pharmacovigilance system cost for small-sized firms and larger-sized firms
Fig. 31: Clinical trial cost by phase (%)
Fig. 32: Selected clinical trials costs based on technology
Fig. 33: Estimated cost of developing therapeutic medical device in the U.S.
Fig. 34: The average monthly cost of illness due to ADRs
Fig. 35: Medical Writers Employers by Industry
Fig. 36: Trending topics on social media (2017)
Fig. 37: ADR detection and from social media data
Fig. 38: Common literature automation tool flow
Fig. 39: Automation processes in PV
Fig. 40: Deterrents to Leveraging the Cloud (Oracle Survey)
Fig. 41: The three-step process to compute signal statistics from search log using big data
Fig. 42: Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Fig. 43: Pharma & Biotech R&D expense growth, 2020 (%)
Fig. 44: Medical writing market outlook, 2022 (USD Million)
Fig. 45: Medical writing market, 2018-2030 (USD Million)
Fig. 46: Global medical safety review market, 2018-2030 (USD Million)
Fig. 47: Pharmacovigilance market: Product life cycle movement analysis
Fig. 48: Pharmacovigilance market product life cycle dashboard
Fig. 49: Global Preclinical market, 2018-2030 (USD Million)
Fig. 50: Global Phase I market, 2018-2030 (USD Million)
Fig. 51: Global Phase II market, 2018-2030 (USD Million)
Fig. 52: Global Phase III market, 2018-2030 (USD Million)
Fig. 53: Adverse events reported in FAERS system, 2019-2022
Fig. 54: Global Phase IV market, 2018-2030 (USD Million)
Fig. 55: Pharmacovigilance market: Service provider movement analysis
Fig. 56: Pharmacovigilance Service provider dashboard
Fig. 57: Global In-house market, 2018-2030 (USD Million)
Fig. 58: Global contract outsourcing market, 2018-2030 (USD Million)
Fig. 59: Pharmacovigilance market: Type movement analysis
Fig. 60: Pharmacovigilance type dashboard
Fig. 61: Global spontaneous reporting market, 2018-2030 (USD Million)
Fig. 62: Global intensified ADR reporting market, 2018-2030 (USD Million)
Fig. 63: Global targeted spontaneous reporting market, 2018-2030 (USD Million)
Fig. 64: Global CEM market, 2018-2030 (USD Million)
Fig. 65: Global EHR mining market, 2018-2030 (USD Million)
Fig. 66: Pharmacovigilance market: Process flow movement analysis
Fig. 67: Pharmacovigilance market process flow dashboard
Fig. 68: Global case data management market, 2018-2030 (USD Million)
Fig. 69: Global case logging market, 2018-2030 (USD Million)
Fig. 70: Global case data analysis market, 2018-2030 (USD Million)
Fig. 71: Global medical reviewing and reporting market, 2018-2030 (USD Million)
Fig. 72: Global signal detection market, 2018-2030(USD Million)
Fig. 73: Global adverse event logging market, 2018-2030 (USD Million)
Fig. 74: Global adverse event analysis market, 2018-2030 (USD Million)
Fig. 75: Global adverse event review & reporting market, 2018-2030 (USD Million)
Fig. 76: Global risk management system market, 2018-2030 (USD Million)
Fig. 77: Global Risk Evaluation System market, 2018-2030 (USD Million)
Fig. 78: Global risk mitigation system market, 2018-2030 (USD Million)
Fig. 79: Pharmacovigilance market: Therapeutic area movement analysis
Fig. 80: Pharmacovigilance market therapeutic area dashboard
Fig. 81: Global oncology market, 2018-2030 (USD Million)
Fig. 82: Global neurology market, 2018-2030 (USD Million)
Fig. 83: Global cardiology market, 2018-2030 (USD Million)
Fig. 84: Global respiratory systems market, 2018-2030 (USD Million)
Fig. 85: Global others market, 2018-2030 (USD Million)
Fig. 86: Pharmacovigilance market: End-use movement analysis
Fig. 87: Pharmacovigilance market end-use dashboard
Fig. 88: Global pharmaceuticals market, 2018-2030 (USD Million)
Fig. 89: Global biotechnology companies’ market, 2018-2030 (USD Million)
Fig. 90: Global medical device manufacturers market, 2018-2030 (USD Million)
Fig. 91: Global others market, 2018-2030 (USD Million)
Fig. 92: Regional market place: Key takeaways
Fig. 93: North America pharmacovigilance market, 2018- 2030 (USD Million)
Fig. 94: U.S. key country dynamics
Fig. 95: U.S. key country dynamics
Fig. 96: U.S. pharmacovigilance market, 2018-2030(USD Million)
Fig. 97: Canada key country dynamics
Fig. 98: Canada key country dynamics
Fig. 99: Canada pharmacovigilance market, 2018-2030 (USD Million)
Fig. 100: Europe pharmacovigilance market, 2018-2030 (USD Million)
Fig. 101: UK key country dynamics
Fig. 102: UK key country dynamics
Fig. 103: UK pharmacovigilance market, 2018-2030 (USD Million)
Fig. 104: Germany key country dynamics
Fig. 105: Germany key country dynamics
Fig. 106: Germany pharmacovigilance market, 2018-2030 (USD Million)
Fig. 107: France key country dynamics
Fig. 108: France key country dynamics
Fig. 109: France pharmacovigilance market, 2018-2030 (USD Million)
Fig. 110: Italy key country dynamics
Fig. 111: Italy key country dynamics
Fig. 112: Italy pharmacovigilance market, 2018-2030 (USD Million)
Fig. 113: Spain key country dynamics
Fig. 114: Spain key country dynamics
Fig. 115: Spain pharmacovigilance market, 2018-2030 (USD Million)
Fig. 116: Russia key country dynamics
Fig. 117: Russia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 118: Denmark key country dynamics
Fig. 119: Denmark key country dynamics
Fig. 120: Denmark pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 121: Norway key country dynamics
Fig. 122: Norway key country dynamics
Fig. 123: Norway pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 124: Sweden key country dynamics
Fig. 125: Sweden key country dynamics
Fig. 126: Sweden pharmacovigilance market estimates and forecasts, 2018-2030, (USD Million)
Fig. 127: Asia Pacific Pharmacovigilance market, 2018-2030 (USD Million)
Fig. 130: Japan pharmacovigilance market, 2018-2030 (USD Million)
Fig. 131: China key country dynamics
Fig. 132: China key country dynamics
Fig. 133: China pharmacovigilance market, 2018-2030 (USD Million)
Fig. 134: India key country dynamics
Fig. 135: India key country dynamics
Fig. 136: India pharmacovigilance market, 2018-2030 (USD Million)
Fig. 139: Australia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 140: Thailand key country dynamics
Fig. 141: Thailand key country dynamics
Fig. 142: Thailand pharmacovigilance market, 2018-2030 (USD Million)
Fig. 145: South Korea pharmacovigilance market, 2018-2030 (USD Million)
Fig. 146: Latin America pharmacovigilance market, 2018-2030 (USD Million)
Fig. 149: Brazil pharmacovigilance market, 2018-2030 (USD Million)
Fig. 150: Mexico key country dynamics
Fig. 152: Mexico pharmacovigilance market, 2018-2030 (USD Million)
Fig. 155: Argentina pharmacovigilance market, 2018-2030 (USD Million)
Fig. 156: MEA pharmacovigilance market, 2018-2030 (USD Million)
Fig. 159: South Africa pharmacovigilance market, 2018-2030 (USD Million)
Fig. 162: Saudi Arabia pharmacovigilance market, 2018-2030 (USD Million)
Fig. 163: UAE key country dynamics
Fig. 164: UAE key country dynamics
Fig. 165: UAE pharmacovigilance market, 2018-2030 (USD Million)
Fig. 167: Kuwait pharmacovigilance market, 2018-2030 (USD Million)
Fig. 168: Market participant categorization
Fig. 169: Company market position analysis
Fig. 170: Estimated company market share analysis, 2022 (%)
Fig. 171: SWOT - Accenture
Fig. 172: SWOT - Linical Americas
Fig. 173: SWOT - IQVIA
Fig. 174: SWOT - Cognizant
Fig. 175: SWOT - Laboratory Corporation of America Holdings
Fig. 176: SWOT - IBM Corporation
Fig. 177: SWOT - ArisGlobal
Fig. 178: SWOT - ICON plc
Fig. 179: SWOT - Capgemini
Fig. 180: SWOT - ITClinical
Fig. 181: SWOT - Take Solutions
Fig. 182: SWOT - Parexel International Corporation
Fig. 183: SWOT - Clario
Fig. 184: SWOT - Wipro
Fig. 185: SWOT - United BioSource LLC
Fig. 186: SWOT - FMD K&L
Fig. 187: Commonly outsourced PV activities
Fig. 188: Vendor selection criteria